
#76 What’s Ahead in Pharmaceutical Antitrust Enforcement? Taking Stock of Key Pharmaceutical Issues and Enforcement Actions
Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]
Posted 3 years ago Tagged antitrust biologics daraprim patent wars pay-for-delay pharmaceutical antitrust pharmaceuticals
Although there is little question as to the need for affordable, accessible, and high-quality pharmaceuticals, […]
Posted 4 years ago Tagged abuse of dominance Article 101 Article 102 discount EU European Commission excessive pricing pay-for-delay pharmaceutical pricing rebate UK CMA
The pricing of pharmaceuticals, and in particular whether prices are “too high” or “excessive”, is […]